Disposition of 10000 shares by Berger Franklin M of Atea Pharmaceuticals at 3.3614 subject to Rule 16b-3
| AVIR Stock | USD 2.99 0.01 0.33% |
Slightly above 62% of Atea Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Atea Pharmaceuticals stock suggests that many investors are alarmed at this time. Atea Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Atea Pharmaceuticals. Many technical investors use Atea Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Atea |
Filed transaction by Atea Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Atea Pharmaceuticals Fundamental Analysis
We analyze Atea Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Atea Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Atea Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Atea Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Atea Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Atea Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Atea Pharmaceuticals Related Equities
| ELEV | Elevation Oncology | 8.06 | ||||
| HEPA | Hepion Pharmaceuticals | 5.56 | ||||
| ENVB | Enveric Biosciences | 3.61 | ||||
| IMMX | Immix Biopharma | 4.37 | ||||
| OCEA | Ocean Biomedical | 20.83 |
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.